Cargando…

A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?

Purpose: High dose monotherapies or drug combinations are used to achieve sufficient analgesia for the treatment of severe chronic low back pain, before invasive therapy options are considered. In order to demonstrate an alternative for an empirical treatment approach, the authors' primary aim...

Descripción completa

Detalles Bibliográficos
Autores principales: Otto, Jan C., Forstenpointner, Julia, Sachau, Juliane, Hüllemann, Philipp, Hukauf, Martin, Keller, Thomas, Gierthmühlen, Janne, Baron, Ralf
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753214/
https://www.ncbi.nlm.nih.gov/pubmed/31572292
http://dx.doi.org/10.3389/fneur.2019.00979
_version_ 1783452854277636096
author Otto, Jan C.
Forstenpointner, Julia
Sachau, Juliane
Hüllemann, Philipp
Hukauf, Martin
Keller, Thomas
Gierthmühlen, Janne
Baron, Ralf
author_facet Otto, Jan C.
Forstenpointner, Julia
Sachau, Juliane
Hüllemann, Philipp
Hukauf, Martin
Keller, Thomas
Gierthmühlen, Janne
Baron, Ralf
author_sort Otto, Jan C.
collection PubMed
description Purpose: High dose monotherapies or drug combinations are used to achieve sufficient analgesia for the treatment of severe chronic low back pain, before invasive therapy options are considered. In order to demonstrate an alternative for an empirical treatment approach, the authors' primary aim was to present an algorithm for the objective identification of treatment predictors. Additionally, the study identified baseline-characteristics in chronic low back pain patients prior to tapentadol PR treatment, as well as scrutinized those patients, either benefitting from a medium/high dose tapentadol PR monotherapy or a combination therapy (medium dose tapentadol PR + pregabalin). Patients and Methods: The statistical approach included data of a previously published randomized, double blind, phase 3b study which compared the effectiveness and safety of tapentadol PR vs. a combination of tapentadol PR and pregabalin. In total, 46 clinical parameters were included in the statistical prediction models which were applied separately either to 50 patients who already responded well during the titration period (i.e., medium dose tapentadol PR) or to 261 patients with in the comparative treatment period [i.e., monotherapy (high dose tapentadol PR) or combination therapy (medium dose tapentadol PR/pregabalin)]. Results: The first statistical model identified three co-variables (NRS-3, PDQ, SQ) with predictive effects on patients responding well (“optimal responders”) to a medium dose tapentadol PR titration. Those patients presented low baseline pain intensity scores, good sleep quality and high painDETECT scores. The second statistical model identified eight co-variables (PDQ, numbness, SF-12 MCS, SF-12 PCS, VAS, HADS-A, HADS-D, SQ) with predictive effects on patients responding to high dose tapentadol PR monotherapy vs. a combination therapy (tapentadol PR + pregabalin). The high dose tapentadol PR responders indicated high painDETECT scores, little numbness and a good mental health status. Whereas, the combination therapy (tapentadol PR + pregabalin) responders were characterized by severe sleep disturbances and little anxiety. Conclusion: The statistical analysis characterized chronic low back pain patients and identified factors contributing to a treatment response. Thus, this retrospective statistical algorithm represents an elegant method, which may contribute to future strategies toward a more individualized and improved mechanism based pain therapy.
format Online
Article
Text
id pubmed-6753214
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67532142019-09-30 A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain? Otto, Jan C. Forstenpointner, Julia Sachau, Juliane Hüllemann, Philipp Hukauf, Martin Keller, Thomas Gierthmühlen, Janne Baron, Ralf Front Neurol Neurology Purpose: High dose monotherapies or drug combinations are used to achieve sufficient analgesia for the treatment of severe chronic low back pain, before invasive therapy options are considered. In order to demonstrate an alternative for an empirical treatment approach, the authors' primary aim was to present an algorithm for the objective identification of treatment predictors. Additionally, the study identified baseline-characteristics in chronic low back pain patients prior to tapentadol PR treatment, as well as scrutinized those patients, either benefitting from a medium/high dose tapentadol PR monotherapy or a combination therapy (medium dose tapentadol PR + pregabalin). Patients and Methods: The statistical approach included data of a previously published randomized, double blind, phase 3b study which compared the effectiveness and safety of tapentadol PR vs. a combination of tapentadol PR and pregabalin. In total, 46 clinical parameters were included in the statistical prediction models which were applied separately either to 50 patients who already responded well during the titration period (i.e., medium dose tapentadol PR) or to 261 patients with in the comparative treatment period [i.e., monotherapy (high dose tapentadol PR) or combination therapy (medium dose tapentadol PR/pregabalin)]. Results: The first statistical model identified three co-variables (NRS-3, PDQ, SQ) with predictive effects on patients responding well (“optimal responders”) to a medium dose tapentadol PR titration. Those patients presented low baseline pain intensity scores, good sleep quality and high painDETECT scores. The second statistical model identified eight co-variables (PDQ, numbness, SF-12 MCS, SF-12 PCS, VAS, HADS-A, HADS-D, SQ) with predictive effects on patients responding to high dose tapentadol PR monotherapy vs. a combination therapy (tapentadol PR + pregabalin). The high dose tapentadol PR responders indicated high painDETECT scores, little numbness and a good mental health status. Whereas, the combination therapy (tapentadol PR + pregabalin) responders were characterized by severe sleep disturbances and little anxiety. Conclusion: The statistical analysis characterized chronic low back pain patients and identified factors contributing to a treatment response. Thus, this retrospective statistical algorithm represents an elegant method, which may contribute to future strategies toward a more individualized and improved mechanism based pain therapy. Frontiers Media S.A. 2019-09-13 /pmc/articles/PMC6753214/ /pubmed/31572292 http://dx.doi.org/10.3389/fneur.2019.00979 Text en Copyright © 2019 Otto, Forstenpointner, Sachau, Hüllemann, Hukauf, Keller, Gierthmühlen and Baron. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Neurology
Otto, Jan C.
Forstenpointner, Julia
Sachau, Juliane
Hüllemann, Philipp
Hukauf, Martin
Keller, Thomas
Gierthmühlen, Janne
Baron, Ralf
A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title_full A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title_fullStr A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title_full_unstemmed A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title_short A Novel Algorithm to Identify Predictors of Treatment Response: Tapentadol Monotherapy or Tapentadol/Pregabalin Combination Therapy in Chronic Low Back Pain?
title_sort novel algorithm to identify predictors of treatment response: tapentadol monotherapy or tapentadol/pregabalin combination therapy in chronic low back pain?
topic Neurology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6753214/
https://www.ncbi.nlm.nih.gov/pubmed/31572292
http://dx.doi.org/10.3389/fneur.2019.00979
work_keys_str_mv AT ottojanc anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT forstenpointnerjulia anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT sachaujuliane anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT hullemannphilipp anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT hukaufmartin anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT kellerthomas anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT gierthmuhlenjanne anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT baronralf anovelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT ottojanc novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT forstenpointnerjulia novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT sachaujuliane novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT hullemannphilipp novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT hukaufmartin novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT kellerthomas novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT gierthmuhlenjanne novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain
AT baronralf novelalgorithmtoidentifypredictorsoftreatmentresponsetapentadolmonotherapyortapentadolpregabalincombinationtherapyinchroniclowbackpain